Abstract 581P
Background
Although colorectal cancer (CRC) survivors often suffer from defecation related symptoms (DRS), there are very few treatment options to improve DRS. Strengthening of abdominal muscles to increase intra-abdominal pressure and pelvic floor exercises to improve pelvic floor dyssynergia may improve DRS in colorectal cancer patients. However, the effects of exercise on DRS have not been studied fully. Therefore, the purpose of this study is to investigate the efficacy of exercise on DRS in CRC.
Methods
A total of 120 CRC who completed surgery and adjuvants therapy were recruited out of 441 approached. 120 participants were randomly assigned to either exercise (EG) or usual care group (CG). The combined weekly supervised and home-based exercise program (12 weeks) includes increase in physical activity (PA) levels to meet the ACSM guideline as well as daily calisthenics exercises. Calisthenics exercises include a total of 12 movements aimed to increase whole body muscle strengths which focused on core and pelvic floor muscles. The primary outcome was DRS score assessed the sum of blood and mucus in stool, stool frequency, abdominal pain, buttock pain, bloating, flatulence, fecal incontinence and embarrassment in EOTRC-QLQ-CR29. A two-way ANOVA repeated measures were used determine group and time interaction. Table: 581P
Effects of exercise on defecatory symptoms
Control | Exercise | p-value | |||
Pre | Post | Pre | Post | ||
Blood in stool | 4.7 ± 9.7 | 4.4 ± 9.1 | 7.2 ± 15.5 | 3.1 ± 8.9 | 0.05 |
Stool frequency | 26.3 ± 27.0 | 20.1 ± 20.5 | 28.7 ± 25.1 | 23.4 ± 23.8 | 0.91 |
Abdominal pain | 14.4 ± 22.4 | 11.7 ± 19.2 | 18.3 ± 24.9 | 10.0 ± 16.6 | 0.21 |
Buttock pain | 12.2 ± 21.2 | 12.8 ± 25.4 | 18.9 ± 30.3 | 12.8 ± 26.1 | 0.08 |
Bloating | 22.8 ± 22.5 | 25.0 ± 25.8 | 34.4 ± 30.7 | 22.8 ± 27.1 | 0.01 |
Flatulence | 21.0 ± 26.0 | 17.7 ± 23.3 | 28.3 ± 33.5 | 21.5 ± 25.1 | 0.42 |
Fecal incontinence | 13.5 ± 20.5 | 13.1 ± 20.5 | 16.9 ± 24.8 | 12.9 ± 25.3 | 0.26 |
Embarrassment | 20.4 ± 26.8 | 16.7 ± 20.8 | 27.6 ± 32.0 | 18.0 ± 25.5 | 0.16 |
Bolds were statistically significant different between pre and post (p<.05), p= Difference between control vs. exercise
Results
Among the 120 participants enrolled, 100 (96.6%) completed the trial with supervised exercise compliance rate of 95%. PA levels increased and fitness levels improved only in the exercise group. Exercise significantly decreased DRS score (6 week - 0 week: CG= -14.0 ± 54.7 vs. EG= - 56.1 ± 99.5, p for group and time interaction = 0.02). Symptom scores in EG include blood and mucus in stool, abdominal pain, buttock pain, bloating, flatulence and embarrassment were improved.
Conclusions
It is concluded that both combined supervised and home-based exercise significantly reduced bowel and defecatory problems in colorectal cancer patients.
Clinical trial identification
This study was approved by The Institutional Review Board of Severance Hospital (IRB No. 4-2018-0841).
Editorial acknowledgement
This study was funded by the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (HA16C0012020020) and Yonsei Signature Research Cluster Program of 2021-22-0009.
Legal entity responsible for the study
The authors.
Funding
The National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea, Yonsei Signature Research Cluster Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
622P - Evaluation of the metastatic colorectal cancer score (mCCS) in predicting outcome for patients with RAS wild type metastatic colorectal cancer (mCRC) treated with first-line (1L) panitumumab (PAN) plus FOLFIRI/FOLFOX: Updated interim results of the non-interventional study VALIDATE
Presenter: Marcel Reiser
Session: Poster session 10
623P - VIC regimen (vemurafenib/irinotecan/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated advanced colorectal cancer
Presenter: Yijiao Chen
Session: Poster session 10
624P - Tolerability and safety of vemurafenib, cetuximab combined with camrelizumab for BRAF V600E-mutated /MSS metastatic colorectal cancer
Presenter: Meng Qiu
Session: Poster session 10
625P - Efficacy and safety of the combination of encorafenib and cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: An AGEO real-world multicentre study
Presenter: Claire Gallois
Session: Poster session 10
626P - Mucinous differentiation (MD) as predictor of response in BRAF-V600E mutated metastatic colorectal cancer (mCRC) treated with BRAF inhibitors (BRAFi) combinations
Presenter: Francisco Javier Ros Montana
Session: Poster session 10